WO2019004713A3 - 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법 - Google Patents

이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법 Download PDF

Info

Publication number
WO2019004713A3
WO2019004713A3 PCT/KR2018/007249 KR2018007249W WO2019004713A3 WO 2019004713 A3 WO2019004713 A3 WO 2019004713A3 KR 2018007249 W KR2018007249 W KR 2018007249W WO 2019004713 A3 WO2019004713 A3 WO 2019004713A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained
ivabradine
release
heart failure
pharmaceutical composition
Prior art date
Application number
PCT/KR2018/007249
Other languages
English (en)
French (fr)
Other versions
WO2019004713A2 (ko
Inventor
동을원
허홍구
김해양
임선주
Original Assignee
에리슨제약(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에리슨제약(주) filed Critical 에리슨제약(주)
Publication of WO2019004713A2 publication Critical patent/WO2019004713A2/ko
Publication of WO2019004713A3 publication Critical patent/WO2019004713A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 이바브라딘을 포함하는 서방성 약제학적 조성물 및 서방성 이바브라딘과 속방성 베타-차단제를 포함하는 심부전 및 협심증 치료용 복합 제제 및 이의 제조방법에 관한 것으로, 이바브라딘 또는 이의 약제학적으로 허용 가능한 염; 및 서방화 기재로서 지방산 알코올 및 지방산 에스테르로부터 선택되는 적어도 하나를 포함하는 서방성 심부전 치료용 약제학적 조성물, 그리고 베타-차단제로서 특히 네비보롤 또는 이의 약제학적으로 허용 가능한 염을 추가로 포함하는 복합 제제는 1 일 1 회 투여로 환자의 약물 준수성과 효과 지속성을 향상시킬 수 있으며, 약물 상호간 상승 작용으로 협심증과 심부전, 특히 만성 심부전에 대한 치료와 함께, 항고혈압 작용 및 이에 의한 심장혈관 질환의 예방 또는 치료 효과를 증강시키면서, 각각의 약물의 부작용을 감소시켜 환자의 순응도를 높일 수 있다.
PCT/KR2018/007249 2017-06-27 2018-06-27 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법 WO2019004713A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0081198 2017-06-27
KR1020170081198A KR20190001340A (ko) 2017-06-27 2017-06-27 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법

Publications (2)

Publication Number Publication Date
WO2019004713A2 WO2019004713A2 (ko) 2019-01-03
WO2019004713A3 true WO2019004713A3 (ko) 2019-03-21

Family

ID=64742401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/007249 WO2019004713A2 (ko) 2017-06-27 2018-06-27 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법

Country Status (2)

Country Link
KR (1) KR20190001340A (ko)
WO (1) WO2019004713A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294777B (zh) * 2020-11-04 2022-07-05 南京康川济医药科技有限公司 一种盐酸伊伐布雷定缓释制剂及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028743A1 (en) * 2000-12-26 2004-02-12 Patrick Wuthrich Solid themoformable pharmaceutical composition for the controlled release of ivabradine
WO2010128525A2 (en) * 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
KR101078133B1 (ko) * 2008-02-14 2011-10-28 르 라보레또레 쎄르비에르 동방 결절 ｉｆ 흐름 억제제와 베타 차단제의 회합체
KR20140045993A (ko) * 2011-08-05 2014-04-17 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이바브라딘 또는 이의 약학적으로 허용가능한 염의 지속-방출형 제제
KR101389879B1 (ko) * 2010-06-15 2014-04-29 르 라보레또레 쎄르비에르 심부전의 치료에서의 동결절 Ｉｆ 전류 억제제 및 안지오텐신-전환 효소 억제제의 회합물의 용도
US9283192B2 (en) * 2010-03-05 2016-03-15 University Of Strathclyde Delayed prolonged drug delivery

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028743A1 (en) * 2000-12-26 2004-02-12 Patrick Wuthrich Solid themoformable pharmaceutical composition for the controlled release of ivabradine
KR101078133B1 (ko) * 2008-02-14 2011-10-28 르 라보레또레 쎄르비에르 동방 결절 ｉｆ 흐름 억제제와 베타 차단제의 회합체
WO2010128525A2 (en) * 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
US9283192B2 (en) * 2010-03-05 2016-03-15 University Of Strathclyde Delayed prolonged drug delivery
KR101389879B1 (ko) * 2010-06-15 2014-04-29 르 라보레또레 쎄르비에르 심부전의 치료에서의 동결절 Ｉｆ 전류 억제제 및 안지오텐신-전환 효소 억제제의 회합물의 용도
KR20140045993A (ko) * 2011-08-05 2014-04-17 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이바브라딘 또는 이의 약학적으로 허용가능한 염의 지속-방출형 제제

Also Published As

Publication number Publication date
KR20190001340A (ko) 2019-01-04
WO2019004713A2 (ko) 2019-01-03

Similar Documents

Publication Publication Date Title
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
TW200738228A (en) Neramexane modified release matrix tablet
JP2019517542A5 (ko)
JP2012505883A5 (ko)
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
FI3294283T3 (fi) Sakubitriili-valsartaani-annostusohjelma sydämen vajaatoiminnan hoitamiseksi
WO2012021107A3 (en) A liposomal formulation for ocular drug delivery
JP2008540405A5 (ko)
KR20100008356A (ko) 칼슘채널길항제를 포함하는 약제학적 제제
RU2014129508A (ru) Новая комбинация
JP2017513809A5 (ko)
WO2020138791A3 (ko) 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2019004713A3 (ko) 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
EA201590474A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
WO2009104916A3 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
RU2021101120A (ru) Сублингвальное или буккальное введение dim для лечения заболеваний кожи
BR112018008835A8 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
UA107716C2 (ru) Терапевтическое средство с замедленным высвобождением на основе соединения 2-фенилтиазола для гипертонии и почечной дисфункции

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18825174

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18825174

Country of ref document: EP

Kind code of ref document: A2